|
MechanismIL-17A inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical Gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Dose-Ranging, Phase 2 Study to Evaluate the Efficacy and Safety of Different Doses of ZL-1102 Topical gel (A Human VH IL-17A Antibody Fragment) in the Treatment of Chronic Plaque Psoriasis
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects With Small Cell Lung Cancer
An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer
一项在中国晚期胃癌或胃食管连接部癌且 FGFR2b 过表达的受试者中进行的 bemarituzumab 联合 mFOLFOX6 和纳武利尤单抗的 1 期研究
[Translation] A phase 1 study of bemarituzumab combined with mFOLFOX6 and nivolumab in Chinese subjects with advanced gastric or gastroesophageal junction cancer and FGFR2b overexpression
主要目的:表征 bemarituzumab 的 PK 特征。
次要目的:评价 bemarituzumab+mFOLFOX6 和纳武利尤单抗的安全性和耐受性。评价 bemarituzumab 的 ADA。
探索性目的:评价 bemarituzumab+mFOLFOX6 和纳武利尤单抗的疗效。
[Translation] Primary objective: Characterize the PK characteristics of bemarituzumab.
Secondary objectives: Evaluate the safety and tolerability of bemarituzumab+mFOLFOX6 and nivolumab. Evaluate the ADA of bemarituzumab.
Exploratory objectives: Evaluate the efficacy of bemarituzumab+mFOLFOX6 and nivolumab.
100 Clinical Results associated with Zai Lab Ltd. (United States)
0 Patents (Medical) associated with Zai Lab Ltd. (United States)
100 Deals associated with Zai Lab Ltd. (United States)
100 Translational Medicine associated with Zai Lab Ltd. (United States)